Keytru­da hit with sec­ond PhI­II set­back this year as Mer­ck­'s block­buster flops cer­tain head and neck tri­al

3 years ago
R&D

Bris­tol My­ers vets tie up an­oth­er all-stock deal, lin­ing up clin­i­cal-stage on­col­o­gy pipeline

3 years ago
Deals
R&D

Dai­ichi Sankyo los­es bid to bat back a $42M patent ver­dict over En­her­tu

3 years ago
Law

Ex­clu­sive: Mark Pruzan­s­ki is once again reach­ing for the brass ring in biotech

3 years ago
Startups
Bioregnum

Gene ther­a­py for ovar­i­an can­cer fails PhI­II study — sink­ing biotech's shares

3 years ago
R&D
Cell/Gene Tx

With a fresh $100M in hand, one RNA start­up is mov­ing to the clin­ic, find­ing part­ners and build­ing a new lab — all ...

3 years ago
Financing

No­var­tis scraps key PD-1 sub­mis­sion, while tout­ing 'sig­nif­i­cant bolt-on M&A fire­pow­er'

3 years ago
Pharma

J&J tones down M&A hype — down­shifts to 'neu­tral po­si­tion' while trim­ming sales guid­ance

3 years ago
Pharma

MD­MA psy­chother­a­py tri­al put on pause af­ter Health Cana­da in­spec­tion

3 years ago
R&D
FDA+

FDA slaps Im­prim­is­Rx with a warn­ing let­ter over spon­sored ar­ti­cles in med­ical jour­nals

3 years ago
Pharma
Marketing

Am­gen, GSK, Re­genxbio and oth­ers urge SCO­TUS to re­view 'dam­ag­ing' de­ci­sion on bio­med­ical patents

3 years ago
R&D
Law

Phar­ma's new 'Ber­lin De­c­la­ra­tion' seeks to re­serve vac­cines, ther­a­peu­tics in pro­duc­tion for low-in­come coun­tries

3 years ago
Coronavirus

WuXi Bi­o­log­ics serves up $1.4B ex­pan­sion of re­search and man­u­fac­tur­ing cen­ter in Sin­ga­pore

3 years ago
Pharma
Manufacturing

Mar­ket­ingRx roundup: Pfiz­er de­buts new ‘Menopause’ pod­cast sea­son; Pfiz­er, Mod­er­na nab top spots on in­no­va­tion ...

3 years ago
Pharma
Marketing

Phar­mas change up lo­gos in June to sig­nal LGT­BQ+ sol­i­dar­i­ty, but ex­perts call for push be­yond ‘rain­bow wash­ing’

3 years ago
Pharma
Marketing

San Fran­cis­co cell ther­a­py play­er lays off 94 staffers as it awaits da­ta on lead can­di­date

3 years ago
People
Cell/Gene Tx

In­cyte nabs sec­ond ap­proval with JAK in­hibitor cream for vi­tili­go

3 years ago
Pharma
FDA+

Af­ter abor­tion rul­ing, biotechs be­hind nov­el con­tra­cep­tives say tide is turn­ing on in­sur­ance cov­er­age

3 years ago
In Focus

As the pan­dem­ic high wanes, In­ovio chops head­count again while chas­ing Covid win

3 years ago
People
R&D

Look­ing to climb out of bear mar­ket and FDA hur­dles, Sum­mit of­fers up $100M worth of stock

3 years ago
Financing
Pharma

Apel­lis nabs pri­or­i­ty re­view for ge­o­graph­ic at­ro­phy pitch; Bris­tol My­ers ex­tends of­fer time­line on Turn­ing Point ...

3 years ago
News Briefing

Mi­cro­cap Viking gets a re­prieve as FDA lifts hold on PhII study for rare meta­bol­ic dis­or­der

3 years ago
FDA+

In bid to avoid im­munother­a­py tox­i­c­i­ties, Car­tog­ra­phy charts a course to­ward modal­i­ty-ag­nos­tic drugs

3 years ago
Financing
Startups

Short­ly af­ter sell­ing Sier­ra to GSK, Stephen Dil­ly heads to en­zyme en­gi­neer Codex­is as new CEO

3 years ago
People
First page Previous page 490491492493494495496 Next page Last page
A service from the Financial Times